aTyr Pharma, Inc. (NASDAQ:ATYR) Given Consensus Rating of “Buy” by Brokerages

Shares of aTyr Pharma, Inc. (NASDAQ:ATYR) have been given an average recommendation of “Buy” by the six research firms that are covering the stock, MarketBeat reports. Five investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $23.25.

Several equities research analysts recently issued reports on ATYR shares. HC Wainwright reissued a “buy” rating and set a $35.00 price objective on shares of aTyr Pharma in a research note on Wednesday, June 4th. Jefferies Financial Group lifted their price objective on aTyr Pharma from $9.00 to $17.00 and gave the company a “buy” rating in a research note on Friday, August 22nd. Wells Fargo & Company lifted their price objective on aTyr Pharma from $17.00 to $25.00 and gave the company an “overweight” rating in a research note on Friday, June 20th. Finally, Wall Street Zen lowered aTyr Pharma from a “hold” rating to a “sell” rating in a research note on Saturday, August 9th.

Institutional Investors Weigh In On aTyr Pharma

Large investors have recently added to or reduced their stakes in the business. California State Teachers Retirement System bought a new stake in aTyr Pharma during the second quarter valued at $28,000. Group One Trading LLC bought a new stake in aTyr Pharma during the fourth quarter valued at $26,000. Ameritas Investment Partners Inc. bought a new stake in aTyr Pharma during the second quarter valued at $45,000. Legal & General Group Plc bought a new stake in aTyr Pharma during the second quarter worth about $49,000. Finally, Raymond James Financial Inc. bought a new stake in aTyr Pharma during the fourth quarter worth about $39,000. Institutional investors own 61.72% of the company’s stock.

aTyr Pharma Price Performance

aTyr Pharma stock opened at $5.61 on Friday. aTyr Pharma has a one year low of $1.67 and a one year high of $7.29. The business has a fifty day moving average price of $5.34 and a 200-day moving average price of $4.33. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.63 and a quick ratio of 5.63. The firm has a market capitalization of $549.72 million, a P/E ratio of -7.01 and a beta of 1.01.

aTyr Pharma (NASDAQ:ATYR) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($0.22) EPS for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.04). As a group, equities research analysts forecast that aTyr Pharma will post -0.91 EPS for the current year.

About aTyr Pharma

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.